Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade

[1]  P. Boekstegers,et al.  Cardiac AAV 9S 100 A 1 gene therapy rescues postischemic heart failure in a preclinical large animal model , 2014 .

[2]  U. Haberkorn,et al.  AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. , 2013, European heart journal.

[3]  M. Bristow.  Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. , 2011, Circulation research.

[4]  P. Boekstegers,et al.  Cardiac AAV9-S100A1 Gene Therapy Rescues Post-Ischemic Heart Failure in a Preclinical Large Animal Model , 2011, Science Translational Medicine.

[5]  Barry Greenberg,et al.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure , 2011, Circulation.

[6]  W. Koch,et al.  G protein-coupled receptor kinases in normal and failing myocardium. , 2011, Frontiers in bioscience.

[7]  D. Leosco,et al.  GRK2 as a novel gene therapy target in heart failure. , 2011, Journal of molecular and cellular cardiology.

[8]  F. von Wegner,et al.  The Inotropic Peptide &bgr;ARKct Improves &bgr;AR Responsiveness in Normal and Failing Cardiomyocytes Through G&bgr;&ggr;-Mediated L-Type Calcium Current Disinhibition , 2011, Circulation research.

[9]  G. Vorobiof,et al.  Small Molecule Disruption of G&bgr;&ggr; Signaling Inhibits the Progression of Heart Failure , 2010, Circulation research.

[10]  V. Jeevanandam,et al.  Reversal of impaired myocardial beta-adrenergic receptor signaling by continuous-flow left ventricular assist device support. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  W. Koch,et al.  Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure. , 2010, Drug discovery today. Disease mechanisms.

[12]  G. Dorn,et al.  Reduction of Sympathetic Activity via Adrenal-targeted GRK2 Gene Deletion Attenuates Heart Failure Progression and Improves Cardiac Function after Myocardial Infarction* , 2010, The Journal of Biological Chemistry.

[13]  W. Koch,et al.  Dynamic Changes in Lymphocyte GRK2 Levels in Cardiac Transplant Patients: A Biomarker for Left Ventricular Function , 2010, Clinical and translational science.

[14]  W. Koch,et al.  Myocardial Adeno-Associated Virus Serotype 6–&bgr;ARKct Gene Therapy Improves Cardiac Function and Normalizes the Neurohormonal Axis in Chronic Heart Failure , 2009, Circulation.

[15]  S. Houser,et al.  G Protein-Coupled Receptor Kinase 2 Ablation in Cardiac Myocytes Before or After Myocardial Infarction Prevents Heart Failure , 2008, Circulation research.

[16]  W. Koch,et al.  Gene therapy in heart failure. , 2008, Circulation research.

[17]  W. Koch,et al.  Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  W. Koch,et al.  Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. , 2007, Trends in molecular medicine.

[19]  M. Gao,et al.  New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy. , 2007, Trends in cardiovascular medicine.

[20]  W. Koch,et al.  Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure , 2007, Nature Medicine.

[21]  O. Brodde.  Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. , 2007, Naunyn-Schmiedeberg's archives of pharmacology.

[22]  O. Brodde.  β-adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[23]  A. Curcio,et al.  Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. , 2006, American journal of physiology. Heart and circulatory physiology.

[24]  H. Rockman,et al.  Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. , 2005, Journal of the American College of Cardiology.

[25]  H. Bruck,et al.  G-protein-coupled receptor kinase activity in human heart failure: Effects of β-adrenoceptor blockade , 2005 .

[26]  H. Bruck,et al.  G-protein-coupled receptor kinase activity in human heart failure: effects of beta-adrenoceptor blockade. , 2005, Cardiovascular research.

[27]  A. Nishiyama,et al.  Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. , 2005, Cardiovascular research.

[28]  W. Koch,et al.  Targeted &bgr;-Adrenergic Receptor Kinase (&bgr;ARK1) Inhibition by Gene Transfer in Failing Human Hearts , 2004 .

[29]  W. Koch,et al.  Viral-based myocardial gene therapy approaches to alter cardiac function. , 2004, Annual review of physiology.

[30]  R. Spang,et al.  Differential myocardial gene expression in the development and rescue of murine heart failure. , 2003, Physiological genomics.

[31]  M. Lohse,et al.  Effects of two Gβγ-binding proteins – N-terminally truncated phosducin and β-adrenergic receptor kinase C terminus (βARKct) – in heart failure , 2003, Gene Therapy.

[32]  R. Lefkowitz,et al.  Keeping G Proteins at Bay: A Complex Between G Protein-Coupled Receptor Kinase 2 and Gßγ , 2003, Science.

[33]  KirstenLeineweber,et al.  Ventricular Hypertrophy Plus Neurohumoral Activation Is Necessary to Alter the Cardiac β-Adrenoceptor System in Experimental Heart Failure , 2002 .

[34]  P. H. Anborgh,et al.  Phosphorylation-independent Regulation of Metabotropic Glutamate Receptor Signaling by G Protein-coupled Receptor Kinase 2* , 2002, The Journal of Biological Chemistry.

[35]  Robert J. Lefkowitz,et al.  Seven-transmembrane-spanning receptors and heart function , 2002, Nature.

[36]  S. Houser,et al.  Patients With End-Stage Congestive Heart Failure Treated With &bgr;-Adrenergic Receptor Antagonists Have Improved Ventricular Myocyte Calcium Regulatory Protein Abundance , 2001, Circulation.

[37]  N. Smedira,et al.  Mechanical Unloading Restores &bgr;-Adrenergic Responsiveness and Reverses Receptor Downregulation in the Failing Human Heart , 2001, Circulation.

[38]  C. Scorer,et al.  Expression of GRK2 is increased in the left ventricles of cardiomyopathic hamsters , 2001, Basic Research in Cardiology.

[39]  M. Packer.  Current role of beta-adrenergic blockers in the management of chronic heart failure. , 2001, The American journal of medicine.

[40]  R. Lefkowitz,et al.  Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  L. Leinwand,et al.  Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. , 2001, The Journal of clinical investigation.

[42]  S. Emani,et al.  In Vivo Ventricular Gene Delivery of a &bgr;-Adrenergic Receptor Kinase Inhibitor to the Failing Heart Reverses Cardiac Dysfunction , 2001, Circulation.

[43]  W. Koch,et al.  - Adrenergic Receptor Kinase Inhibitor β Transfer of a Ventricular Dysfunction After Cardioplegic Arrest Is Improved After Myocardial Gene , 2001 .

[44]  M. Sallese,et al.  Selective regulation of Gq signaling by G protein-coupled receptor kinase 2: direct interaction of kinase N terminus with activated galphaq. , 2000, Molecular pharmacology.

[45]  J L Benovic,et al.  Regulation of G protein-coupled receptor kinases. , 2000, Trends in cardiovascular medicine.

[46]  N. Dzimiri.  Regulation of β-Adrenoceptor Signaling in Cardiac Function and Disease , 1999 .

[47]  D. Mann,et al.  Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.

[48]  N. Dzimiri.  Regulation of b-Adrenoceptor Signaling in Cardiac Function and Disease , 1999 .

[49]  R. Willette,et al.  The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. , 1999, Hypertension.

[50]  R. Lefkowitz,et al.  Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. , 1998, Circulation.

[51]  J. Ross,et al.  Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  W. Koch,et al.  Mechanism of β-Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased β-Adrenergic Receptor Kinase* , 1997, The Journal of Biological Chemistry.

[53]  J. Benovic,et al.  G-protein-coupled receptor kinase activity is increased in hypertension. , 1997, The Journal of clinical investigation.

[54]  W. Abraham,et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.

[55]  M. Lohse,et al.  Activation of β-Adrenergic Receptor Kinase During Myocardial Ischemia , 1996 .

[56]  M. Steinfath,et al.  Effects of metoprolol on myocardial β-adrenoceptors and Giα-proteins in patients with congestive heart failure , 1996, European Journal of Clinical Pharmacology.

[57]  R. Lefkowitz,et al.  Mutational Analysis of the Pleckstrin Homology Domain of the β-Adrenergic Receptor Kinase. , 1995, The Journal of Biological Chemistry.

[58]  M. Böhm,et al.  Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. , 1994, Circulation research.

[59]  R. Lefkowitz,et al.  The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. , 1993, The Journal of biological chemistry.

[60]  M. Böhm,et al.  Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.

[61]  H. Valantine,et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. , 1989, Circulation.

[62]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.